Cell, Gene, and Advanced Therapeutic Expertise

Cell, gene, and advanced therapies (CGAT) are accelerating and bringing fresh hope to patients, often in areas of significant unmet need with no existing treatment alternatives. Yet getting these therapies to market is far from simple. High development costs, complex delivery models, fragmented stakeholder decision-making, and evolving evidence of expectations can slow access and diminish value for patients and healthcare systems.

Development pipelines are increasingly targeting more prevalent chronic conditions, and as these programs advance toward commercialization, patient volumes will grow rapidly, placing even greater pressure on healthcare systems.

A winning strategy depends on the right balance of risk and reward across your portfolio. We can guide you through every aspect of therapy exploration, early development planning, regulatory strategy, clinical development, manufacturing, and commercialization.